AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

(2022) Domenica M. Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

(2022) Takashi Kadowaki et al.   Lancet Diabetes & Endocrinology

Tirzepatide Once Weekly for the Treatment of Obesity

(2022) Ania M. Jastreboff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in the Incidence of Childhood Obesity

(2022) Solveig A. Cunningham et al.   PEDIATRICS

Pharmacogenomics of Medication‐Induced Weight Gain and Antiobesity Medications

(2021) Sneha Singh et al.   Obesity

Use of Weight Loss Medications in Patients after Bariatric Surgery

(2021) Ilana P. Redmond et al.   Current Obesity Reports

Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the U.S.

(2021) Karine Suissa et al.   DIABETES OBESITY & METABOLISM

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

(2021) Melanie Davies et al.   LANCET

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity

(2021) Thiruvengadam Muniraj et al.   GASTROENTEROLOGY

AGA Technical Review on Intragastric Balloons in the Management of Obesity

(2021) Raj Shah et al.   GASTROENTEROLOGY

Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes

(2021) Rita R. Kalyani   NEW ENGLAND JOURNAL OF MEDICINE

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

(2021) Julie R. Lundgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic

(2021) Andres Acosta et al.   Obesity

Semaglutide for obesity: four STEPs forward, but more to come

(2021) Donna H Ryan   Lancet Diabetes & Endocrinology

Three- and six-month efficacy and safety of phentermine in a Mexican obese population

(2021) Maribel Márquez-Cruz et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

(2021) Juan P. Frías et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Safety and Superiority of Anti-Obesity Medications

(2021) Muath Alobaida et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

(2021) Anne Flint et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Trends in Obesity Prevalence Among Adults Aged 18 Through 25 Years, 1976-2018

(2021) Alejandra Ellison-Barnes et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

(2021) Qingyang Shi et al.   LANCET

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

(2020) W. Timothy Garvey et al.   DIABETES CARE

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

(2020) Thomas A. Wadden et al.   Obesity

SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design

(2020) Donna H. Ryan et al.   AMERICAN HEART JOURNAL

Obesity in adults: a clinical practice guideline

(2020) Sean Wharton et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome

(2020) Robert Haws et al.   DIABETES OBESITY & METABOLISM

Addressing Disparities in the Management of Obesity in Primary Care Settings

(2020) Thomas A. Wadden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacotherapy for Obesity—Trends Using a Population Level National Database

(2020) Abbinaya Elangovan et al.   OBESITY SURGERY

Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial

(2020) Henrik Gudbergsen et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon—a Case-Matched Study

(2020) Dilhana Badurdeen et al.   OBESITY SURGERY

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

(2020) Karine Clément et al.   Lancet Diabetes & Endocrinology

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Effectiveness of Longer‐Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort

(2019) Kristina H. Lewis et al.   Obesity

The Discovery and Development of Liraglutide and Semaglutide

(2019) Lotte Bjerre Knudsen et al.   Frontiers in Endocrinology

Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials

(2019) Navneet Singh et al.   BMJ Open

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009‐2015

(2019) David R. Saxon et al.   Obesity

Obesity Pharmacotherapy

(2018) Katherine H. Saunders et al.   MEDICAL CLINICS OF NORTH AMERICA

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

(2018) Patrick M O'Neil et al.   LANCET

Phentermine

(2018) Soobin Lim et al.   ANNALS OF PLASTIC SURGERY

A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss

(2018) Frank L. Greenway et al.   Obesity

Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial

(2018) Thomas A. Wadden et al.   Obesity

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

(2017) Carel W le Roux et al.   LANCET

Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial

(2016) ME Mooney et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

(2016) W. Timothy Garvey et al.   Endocrine Practice

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events

(2016) Rohan Khera et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s

(2016) Catherine E. Thomas et al.   Obesity

Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial

(2015) Herman Soto-Molina et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

(2015) Caroline M. Apovian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?

(2015) Donald A. Williamson et al.   Obesity

Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release

(2014) W. Timothy Garvey et al.   DIABETES CARE

How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals

(2014) Stacy L. Schmidt et al.   OBESITY SURGERY

Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials

(2014) S. U. Dombrowski et al.   BMJ-British Medical Journal

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

(2013) Michael D. Jensen et al.   CIRCULATION

The AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence

(2013) Shahnaz Sultan et al.   Clinical Gastroenterology and Hepatology

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

(2013) P. Hollander et al.   DIABETES CARE

A comparative study of five centrally acting drugs on the pharmacological treatment of obesity

(2013) H Suplicy et al.   INTERNATIONAL JOURNAL OF OBESITY

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults

(2013) Louis J. Aronne et al.   Obesity

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

Use of topiramate in pregnancy and risk of oral clefts

(2012) Andrea V. Margulis et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Zonisamide for Weight Reduction in Obese Adults

(2012) Kishore M. Gadde et al.   ARCHIVES OF INTERNAL MEDICINE

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

(2011) W Timothy Garvey et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

GRADE guidelines: 3. Rating the quality of evidence

(2011) Howard Balshem et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

GRADE guidelines 6. Rating the quality of evidence—imprecision

(2011) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long-Term Phentermine Pharmacotherapy for Obesity

(2011) Ed J. Hendricks et al.   Obesity

Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

(2011) David B. Allison et al.   Obesity

Serotonin receptors and heart valve disease—It was meant 2B

(2011) Joshua D. Hutcheson et al.   PHARMACOLOGY & THERAPEUTICS

Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity

(2010) J. G. Kang et al.   DIABETES OBESITY & METABOLISM

Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

(2010) Giuseppe Derosa et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial

(2010) Thomas A. Wadden et al.   Obesity

Nephrolithiasis in topiramate users

(2010) Naim M. Maalouf et al.   UROLOGICAL RESEARCH

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

(2009) Charles S. Wilcox et al.   ADDICTIVE BEHAVIORS

Combination pharmaceutical therapies for obesity

(2009) Kishore M Gadde et al.   EXPERT OPINION ON PHARMACOTHERAPY

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

(2009) C Cercato et al.   INTERNATIONAL JOURNAL OF OBESITY

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Rational Design of a Combination Medication for the Treatment of Obesity

(2008) Frank L. Greenway et al.   Obesity